AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly lowered the mean seated ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients with uncontrolled or treatment-resistant hypertension, AstraZeneca ...

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...

An international team of researchers led by Professor Morris Brown FRS at Queen Mary University of London found that ...

European shares ended slightly lower on Monday, with tariff-sensitive auto stocks down after U.S. President Donald Trump's ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...